Last updated 2026-07-26
TL;DR
DSIP human research is limited to a handful of small trials, mostly from the 1980s and 1990s, with mixed results on sleep architecture and some signal in stress-hormone and opioid/alcohol withdrawal contexts. No modern, adequately powered, placebo-controlled trial confirms it as a sleep aid. It is not FDA-approved for any use.
What is DSIP and why did researchers start testing it in humans?
DSIP (delta sleep-inducing peptide) is a nonapeptide first isolated from rabbit brain tissue in the early 1970s by Swiss researcher Monique Schoenenberger and colleagues, who reported it after collecting blood from sleeping rabbits and looking for factors that could induce slow-wave (delta) sleep in other animals [1]. The peptide's name comes directly from that original animal finding, not from a confirmed human sleep effect. Throughout the late 1970s and into the 1980s, small groups in Europe (mostly Switzerland and Germany) ran human pilot studies to see if the same delta-sleep induction would show up in people. These were era-typical for peptide research at the time: tiny samples, open-label or lightly controlled designs, and outcome measures based on older EEG scoring conventions. Some found modest changes in sleep-stage timing; others found nothing worth reporting. That inconsistency has never really been resolved because almost no one has repeated the work with modern methods. It's worth being blunt about scale here: the entire published human literature on DSIP is a few dozen papers total, and many of them overlap in authorship (the Schoenenberger-Gerardy-Sandyk network in the 1980s produced a large share of it). There is no multi-center trial, no large randomized cohort, and no industry-funded confirmatory study, because DSIP was never picked up as a drug candidate at that scale.
Did DSIP actually improve sleep in human trials?
The honest answer is: sometimes, in tiny studies, with effects that don't hold up as a clean, repeatable sleep-architecture story. A frequently cited early trial gave DSIP intravenously to a small group of insomnia patients and reported some increase in subjective sleep quality and shifts in sleep-stage distribution, but sample sizes were commonly under 20 subjects and designs varied trial to trial [2]. A separate strand of work looked at DSIP not as a nightly sleep aid but as a modifier of stress physiology around sleep, in populations like shift workers or people under psychological stress, with mixed subjective improvement reported in some small cohorts [3]. These aren't the same claim as "DSIP restores deep sleep in healthy adults," and conflating them is where a lot of supplement marketing goes wrong. No study in the modern era (say, the last two decades) has replicated DSIP's sleep effects using current polysomnography standards, actigraphy, or adequately powered, pre-registered designs. That's the gap. If you're looking for a trial that looks like a 2020s FDA-registration sleep study, it doesn't exist for DSIP.
What does the animal research on DSIP actually show, and how is it different from human data?
The original and most consistent DSIP findings are preclinical: injecting the peptide into rabbits and rats produced measurable increases in slow-wave (delta) EEG activity during sleep, which is what generated the name and the initial excitement [1]. Later animal work extended this into looking at DSIP's relationship to circadian rhythm, stress hormone regulation, and opioid withdrawal symptoms in rodent models [4]. That animal signal is real, in the sense that it was measured and published. What it doesn't do is transfer cleanly to humans. Species differences in peptide metabolism, blood-brain barrier penetration, and dosing scale mean an effect in a rat is not evidence of the same effect at the same relative dose in a person. This is a standard translational problem in peptide pharmacology, not something specific to DSIP, but it matters more here because DSIP never went through the later-phase human trials that would normally sort out whether the animal signal holds. Anyone telling you DSIP "is proven to increase delta sleep" without specifying species is skipping over exactly this gap. The proof is in animals. The human proof is thin and old.
Is there human evidence for DSIP and stress hormone (cortisol/ACTH) regulation?
This is actually where some of the more interesting, though still small, human data sits. A few studies from the 1980s looked at DSIP's effect on the hypothalamic-pituitary-adrenal (HPA) axis, including ACTH and cortisol responses, in humans under stress or in patients with specific endocrine conditions, reporting some blunting of stress-hormone spikes with DSIP administration [5]. There's also older clinical work on DSIP in opioid and alcohol withdrawal. A study published in the Soviet/Russian and Western literature in the late 1980s examined DSIP's effect on withdrawal symptom severity in patients dependent on opioids or alcohol, reporting reduced withdrawal symptom scores in treated groups compared to controls in small samples [6]. These are genuinely part of the human record and get cited a lot, but again: small n, older diagnostic and statistical standards, and no modern replication. If you're researching DSIP for a stress-response angle rather than pure sleep, this is the piece of the literature that's a little more substantive than the sleep-architecture claims, but "a little more substantive" still means small, dated trials, not a confirmed mechanism.
How strong is the overall clinical evidence for DSIP as a sleep aid?
| Animal sleep EEG | Multiple studies, 1970s-80s, consistent delta-wave signal [1] | Already established in rodents/rabbits | |
|---|---|---|---|
| Human sleep architecture | A handful of small trials (n often <20), mixed results [2] | Adequately powered, PSG-based RCT, modern era | |
| Human HPA-axis/stress | Small studies showing blunted cortisol/ACTH response [5] | Replication with modern hormone assays, larger n | |
| Withdrawal symptom relief | Small trials in opioid/alcohol withdrawal, 1980s [6] | Modern RCT with standardized withdrawal scales | |
| Regulatory approval | None; not FDA-approved for any indication | Full IND-to-NDA pipeline, which has not been pursued | This table is the honest summary: strong-ish preclinical signal, thin human signal, zero regulatory validation. |
Weak, by any current evidence-grading standard. There is no Cochrane review, no meta-analysis, and no regulatory-agency evaluation of DSIP for insomnia or any other condition. The National Center for Biotechnology Information's PubMed index shows the DSIP literature clustering heavily in the 1977-1995 range, with a sharp drop-off in new primary human trials after that. Compare that pattern to an approved sleep drug and the gap is obvious. Approved hypnotics go through Phase 1 through Phase 3 trials with hundreds to thousands of subjects, FDA review of the full data package, and post-market surveillance. DSIP has none of that pipeline. It sits in the category of "peptide with some old, small human data and active research interest" rather than "peptide with clinical trial-grade efficacy evidence." | Evidence type | What exists for DSIP | What it would take to call it proven |
Why hasn't DSIP been studied more in modern human trials?
A few practical reasons converge here. First, DSIP's original discovery and peak research interest happened before the modern peptide-drug boom and before current trial infrastructure (registries, standardized PSG, pre-registration) became the norm, so a lot of the foundational work is stuck using older methods [1]. Second, no pharmaceutical company has picked DSIP up as a commercial drug candidate. Without a sponsor willing to fund Phase 2/3 trials, a peptide like this tends to stay in academic-curiosity territory. That's a funding and incentive problem, not necessarily a statement that the compound doesn't work; it's just that nobody has put up the money to find out properly. Third, DSIP research is currently classified for research use only in the U.S., meaning it's sold to laboratories for non-human research rather than as an approved or even investigational human drug . That regulatory status itself limits how it gets studied through formal human trial channels now.
What is DSIP's current legal and research status in the U.S.?
DSIP has no FDA approval for any human indication, and it is not classified as a dietary supplement either. It's typically sold and marketed as "research use only," meaning U.S. suppliers position it for laboratory and preclinical research rather than for human consumption . That label matters because it tells you the regulatory system has not evaluated DSIP's safety or efficacy in humans the way it would for an approved drug. This is a separate question from whether the peptide "works." A compound can have real biological activity and still lack the safety and efficacy dossier that regulators require before greenlighting human use. DSIP is squarely in that middle zone: documented biological activity in animals, some human data, no approval. If you want the detail on how this affects sourcing and legitimate purchase channels, that's covered separately at buy DSIP.
What side effects or safety signals showed up in the human studies?
The published human trials, small as they are, generally reported DSIP as well tolerated at the doses tested, without major adverse events described in the papers from the 1980s cohorts [2] [5]. That's a genuinely reassuring note within a thin literature, but it comes with a big caveat: small trials with a few dozen subjects total are not statistically equipped to catch rare or moderate-frequency side effects. A trial of 15-20 people can miss an adverse event that shows up in 1 in 200 users. There is no large-scale, modern human safety database for DSIP. No post-market surveillance exists because there's no market approval to surveil. Anyone using DSIP outside a supervised research setting is operating without the safety net that normally comes with an approved drug's adverse-event reporting system. For a fuller rundown of documented and theoretical side effects, see DSIP peptide side effects.
How does DSIP's evidence compare to melatonin or other sleep-research peptides?
Melatonin has an enormous, modern, ongoing human trial base, including large randomized controlled trials and systematic reviews, plus FDA recognition as a dietary supplement ingredient with a documented safety profile in adults at typical doses. DSIP has none of that infrastructure: no large RCTs, no systematic reviews, no supplement-category regulatory clarity. That doesn't mean DSIP is "proven weaker"; it means the two compounds aren't in comparable evidence tiers at all. Melatonin's literature lets you ask nuanced questions (optimal dose, timing, formulation). DSIP's literature can barely answer the basic question of whether it reliably changes sleep architecture in humans, because so few modern trials exist to ask it in. If your actual goal is falling asleep faster or sleeping longer with an evidence base you can stand on, melatonin or CBT-I (cognitive behavioral therapy for insomnia, which has strong RCT support) are simply better-supported options right now. DSIP belongs in the "interesting research history, unproven clinical tool" category.
What questions does DSIP human research still need to answer?
The list is long, and that's the point: this is still an open research area, not a settled one. Researchers would need a properly powered, placebo-controlled, polysomnography-based trial in adults with diagnosed insomnia to know whether DSIP changes objective sleep architecture at all, more than subjective reports. Dose-response data is basically absent. The old trials used varying IV and injection protocols without a modern pharmacokinetic model behind them, so nobody has a clean answer on optimal dose, timing, or route for a hypothetical human sleep effect. If you want the practical dosing conversation as it stands today (protocol patterns people use, not clinical guidance), that's covered at DSIP dosage and the DSIP dosage calculator. Long-term safety data over months or years of use doesn't exist. Neither does data on interactions with common sleep medications, alcohol, or other peptides. Anyone claiming otherwise is extrapolating well past what's published.
So is DSIP worth trying based on the human evidence?
Here's the straight take: if you're deciding based purely on the strength of human clinical trial evidence, DSIP is one of the weaker-supported peptides in the sleep-and-stress research conversation, not because it's been disproven, but because it's barely been tested at modern standards. The name promises more than the data delivers. If you're a researcher and the goal is exploring the stress-hormone or withdrawal angle in a lab setting, the older literature at least gives you a starting hypothesis and dosing ballpark to design around [5] [6]. If your goal is a consumer sleep aid with confidence behind it, this isn't that, and no amount of marketing copy changes what the trials actually show. For sourcing peptide labeled for research use, DSIP Peptide's site works through a provider-reviewed process and names the fulfilling pharmacy partner directly rather than compounding or shipping product itself; that's the legitimate lane to look at if you're going to pursue this at all, alongside reading the primary literature yourself rather than taking a vendor's summary of it. Start with the general DSIP overview if you haven't already, and check DSIP peptide injection for how the research protocols are typically structured.
Frequently asked questions
Has DSIP been tested in a large human clinical trial?
No. The largest published human DSIP studies still involve small samples, typically under a few dozen subjects, mostly from the 1970s-1990s. There is no large-scale, modern, placebo-controlled trial with hundreds or thousands of participants, which is the standard needed to establish clinical efficacy confidently.
Is DSIP FDA-approved for sleep?
No. DSIP has no FDA approval for insomnia or any other condition. It is generally sold as a research-use-only compound in the U.S., not as an approved drug or regulated dietary supplement, so it hasn't gone through the FDA's efficacy or safety review process.
What was the original DSIP study that gave it its name?
Researchers led by Monique Schoenenberger isolated a nonapeptide from the blood of sleeping rabbits in the early 1970s and found it induced delta (slow-wave) sleep when given to other animals, which is where the name delta sleep-inducing peptide comes from. That foundational finding is an animal study, not a human one.
Does DSIP reduce cortisol in humans?
Some small human studies from the 1980s reported blunted ACTH and cortisol responses to stress after DSIP administration, suggesting an effect on the HPA axis. Sample sizes were small and the work hasn't been replicated with modern hormone assays, so this remains a preliminary finding rather than an established effect.
Does DSIP help with opioid or alcohol withdrawal?
Small older trials, mostly from the late 1980s, reported reduced withdrawal symptom severity in patients given DSIP during opioid or alcohol withdrawal. These studies used small samples and older statistical standards, so the finding is suggestive rather than confirmed by modern-quality research.
Why isn't there more recent research on DSIP in humans?
No pharmaceutical company has sponsored later-phase trials, and DSIP currently sits in a research-use-only regulatory category rather than an approved or investigational drug pathway. Without commercial sponsorship or a formal trial pipeline, the compound has largely stayed in academic literature from the 1970s-90s.
Is DSIP safe based on the human studies that exist?
The small human trials reported DSIP as generally well tolerated at tested doses, without major adverse events described in the papers. But these studies were too small and short to detect rare or moderate-frequency side effects, so there's no real modern human safety database to rely on.
How is DSIP different from melatonin in terms of evidence?
Melatonin has a large, ongoing base of modern randomized controlled trials and recognized supplement status with documented dosing guidance. DSIP has a small, mostly decades-old literature with no large RCTs and no supplement or drug approval, putting it in a much thinner evidence category.
Can DSIP's animal research be used as proof it works in humans?
Not reliably. The clearest DSIP findings, increased delta-wave EEG activity, come from rabbit and rat studies. Species differences in metabolism and dosing mean an animal effect doesn't automatically confirm a human one, and DSIP never went through the later-stage human trials that would settle that question.
What would it take to prove DSIP works for sleep in humans?
Researchers would need an adequately powered, placebo-controlled trial using modern polysomnography in adults with diagnosed insomnia, plus dose-response and long-term safety data. None of that currently exists for DSIP, which is why its human sleep efficacy remains unconfirmed rather than proven or disproven.
Is DSIP legal to buy in the United States?
DSIP is typically sold in the U.S. as a research-use-only compound for laboratory purposes, not as an approved human drug or dietary supplement. Buyers should understand that regulatory status before purchasing, and should look at provider-reviewed sourcing information rather than assuming supplement-level oversight applies.
Does DSIP have any modern (post-2000) human trials?
Very few. The bulk of the human DSIP literature clusters between 1977 and the mid-1990s. There has not been a wave of modern, registered clinical trials replicating or extending those findings, which is a major reason its human evidence base is considered old and thin.
Sources
- NCBI PubMed - Schoenenberger GA, Monnier M, original DSIP isolation research: DSIP was isolated from the blood of sleeping rabbits and shown to induce delta (slow-wave) sleep in animal studies
- NCBI PubMed - human DSIP sleep trial data: Small human trials of DSIP reported mixed changes in sleep quality and sleep-stage distribution using older EEG methods
- NCBI PubMed - DSIP and stress-related sleep research: DSIP was studied in small cohorts under psychological or physiological stress with mixed subjective sleep improvement reported
- NCBI PubMed - DSIP animal research on circadian and stress physiology: Animal studies extended DSIP research into circadian rhythm and opioid withdrawal-related physiology in rodent models
- NCBI PubMed - DSIP effects on ACTH and cortisol in humans: Small human studies reported blunted ACTH and cortisol stress responses after DSIP administration
- NCBI PubMed - DSIP in opioid and alcohol withdrawal treatment studies: Small clinical studies reported reduced withdrawal symptom severity in opioid- or alcohol-dependent patients given DSIP